You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethadone
Accession NumberDB00333  (APRD00485)
TypeSmall Molecule
GroupsApproved
Description

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3).

In Australia methadone is a Schedule 8 (controlled) drug.

Structure
Thumb
Synonyms
(+-)-Methadone
(+/-)-Methadone
(±)-methadone
6-Dimethylamino-4,4-diphenyl-3-heptanone
dl-Methadone
Methadonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disketstablet40 mg/1oralRoxane Laboratories, Inc1973-03-14Not applicableUs
Dolophinetablet5 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Dolophinetablet10 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Dolophine Hydrochloridetablet5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Dolophine Hydrochloridetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Metadoltablet1 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadolsolution1 mgoralPaladin Labs Inc2003-07-11Not applicableCanada
Metadoltablet25 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadolliquid10 mgoralPaladin Labs Inc2000-05-05Not applicableCanada
Metadoltablet10 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadoltablet5 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadol-Dtablet5 mgoralPaladin Labs IncNot applicableNot applicableCanada
Metadol-Dtablet25 mgoralPaladin Labs IncNot applicableNot applicableCanada
Metadol-Dtablet1 mgoralPaladin Labs IncNot applicableNot applicableCanada
Metadol-Dsolution1 mgoralPaladin Labs Inc2014-08-18Not applicableCanada
Metadol-Dliquid10 mgoralPaladin Labs Inc2001-08-03Not applicableCanada
Metadol-Dtablet10 mgoralPaladin Labs IncNot applicableNot applicableCanada
Methadone Hydrochloridetablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralSTAT Rx USA LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridepowder1 g/goralMallinckrodt, Inc.2012-04-30Not applicableUs
Methadone Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousMylan Institutional LLC1947-08-13Not applicableUs
Methadoseconcentrate10 mg/mLoralUnit Dose Services2010-03-10Not applicableUs
Methadoseconcentrate10 mg/mLoralAtlantic Biologicals Corps2010-03-10Not applicableUs
Methadosesolution10 mgoralMallinckrodt Canada Ulc2013-01-03Not applicableCanada
Methadosesolution10 mgoralMallinckrodt Canada Ulc2013-01-03Not applicableCanada
Methadoseconcentrate10 mg/mLoralMallinckrodt, Inc.2010-03-10Not applicableUs
Methadose Sugar-freeconcentrate10 mg/mLoralMallinckrodt, Inc.2010-03-10Not applicableUs
PMS-methadonetablet25 mgoralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadonetablet10 mgoralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadonetablet5 mgoralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadonetablet1 mgoralPaladin Labs IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methadone Hydrochloridetablet10 mg/1oralVista Pharm, Inc.1998-05-29Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralSTAT Rx USA LLC2009-05-19Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralRoxane Laboratories, Inc1988-04-30Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralAscend Laboratories, LLC2012-01-16Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-11Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralbryant ranch prepack2009-05-19Not applicableUs
Methadone Hydrochloridetablet40 mg/1oralMallinckrodt, Inc.2010-08-31Not applicableUs
Methadone Hydrochloridesolution5 mg/5mLoralAtlantic Biologicals Corps1981-05-22Not applicableUs
Methadone Hydrochloridesolution10 mg/5mLoralVista Pharm Inc2010-08-01Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralPhysicians Total Care, Inc.2007-03-12Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralAurolife Pharma, LLC2015-09-15Not applicableUs
Methadone Hydrochloridesolution5 mg/5mLoralVista Pharm Inc2010-08-01Not applicableUs
Methadone Hydrochloridesolution10 mg/5mLoralRoxane Laboratories, Inc.1982-08-30Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralPhysicians Total Care, Inc.2004-01-07Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralAurolife Pharma, LLC2015-09-15Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralVista Pharm Inc2011-12-01Not applicableUs
Methadone Hydrochloridesolution5 mg/5mLoralRoxane Laboratories, Inc.1981-05-22Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralMajor Pharmaceuticals2012-01-16Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralH.J. Harkins Company Inc.2009-05-19Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralVista Pharm Inc2009-10-30Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralRoxane Laboratories, Inc1988-09-06Not applicableUs
Methadone Hydrochloridetablet40 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralH.J. Harkins Company Inc.2009-05-19Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralMallinckrodt, Inc.2009-05-19Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-01-16Not applicableUs
Methadone Hydrochloridetablet40 mg/1oralVista Pharm, Inc.1998-03-25Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralSTAT Rx USA LLC2009-05-19Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralRoxane Laboratories, Inc1988-04-30Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralAmerican Health Packaging2014-10-02Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-15Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralMallinckrodt, Inc.2009-05-19Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralbryant ranch prepack2009-05-19Not applicableUs
Methadosetablet5 mg/1oralMallinckrodt, Inc.2010-02-23Not applicableUs
Methadose Dispersibletablet40 mg/1oralMallinckrodt, Inc.2010-08-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdolanNot Available
DepridolNot Available
HeptadonNot Available
HeptanonNot Available
KetalginNot Available
MephenonNot Available
PhyseptoneNot Available
PolamidonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methadone Hydrochloride
1095-90-5
Thumb
  • InChI Key: FJQXCDYVZAHXNS-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.18594223
  • Average Mass: 345.906
DBSALT000346
Categories
UNIIUC6VBE7V1Z
CAS number76-99-3
WeightAverage: 309.4452
Monoisotopic: 309.209264491
Chemical FormulaC21H27NO
InChI KeyInChIKey=USSIQXCVUWKGNF-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
IUPAC Name
6-(dimethylamino)-4,4-diphenylheptan-3-one
SMILES
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Aralkylamine
  • Gamma-aminoketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.
PharmacodynamicsMethadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.
Mechanism of actionMethadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.
Related Articles
AbsorptionWell absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.
Volume of distribution
  • 1.0 to 8.0 L/kg
Protein bindingIn plasma, methadone is predominantly bound to α1-acid glycoprotein (85% to 90%).
Metabolism

Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.

SubstrateEnzymesProduct
Methadone
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)Details
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)
2-Ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP)Details
Route of eliminationThe elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.
Half life24-36 hours
Clearance
  • 1.4 to 126 L/h
ToxicityIn severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methadone Metabolism PathwayDrug metabolismSMP00624
Methadone Action PathwayDrug actionSMP00408
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9772
Caco-2 permeable+0.7841
P-glycoprotein substrateSubstrate0.6224
P-glycoprotein inhibitor IInhibitor0.7627
P-glycoprotein inhibitor IINon-inhibitor0.9101
Renal organic cation transporterNon-inhibitor0.5851
CYP450 2C9 substrateNon-substrate0.7822
CYP450 2D6 substrateNon-substrate0.7743
CYP450 3A4 substrateSubstrate0.66
CYP450 1A2 substrateInhibitor0.5312
CYP450 2C9 inhibitorNon-inhibitor0.864
CYP450 2D6 inhibitorInhibitor0.5449
CYP450 2C19 inhibitorNon-inhibitor0.8177
CYP450 3A4 inhibitorNon-inhibitor0.5507
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6586
Ames testNon AMES toxic0.946
CarcinogenicityCarcinogens 0.6315
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity3.5250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.947
hERG inhibition (predictor II)Inhibitor0.7606
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Vistapharm inc
  • Mallinckrodt chemical inc
  • Bioniche pharma usa llc
  • Sandoz inc
  • Mallinckrodt inc
  • The pharmanetwork llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral40 mg/1
Tabletoral10 mg/1
Tabletoral5 mg/1
Liquidoral10 mg
Tabletoral1 mg
Tabletoral10 mg
Tabletoral25 mg
Tabletoral5 mg
Solutionoral1 mg
Concentrateoral10 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous10 mg/mL
Powderoral1 g/g
Solutionoral10 mg/5mL
Solutionoral5 mg/5mL
Solutionoral10 mg
Prices
Unit descriptionCostUnit
Methadone hcl 10 mg/ml vial7.48USD ml
Methadone hcl powder5.91USD g
Metadol 25 mg Tablet1.69USD tablet
Metadol 10 mg Tablet0.9USD tablet
Methadone intensol 10 mg/ml0.85USD ml
Metadol 5 mg Tablet0.56USD tablet
Methadone hcl 10 mg tablet0.37USD tablet
Metadol Concentrate 10 mg/ml Liquid0.37USD ml
Methadone hcl 5 mg tablet0.34USD tablet
Dolophine hcl 10 mg tablet0.21USD tablet
Metadol 1 mg Tablet0.17USD tablet
Methadose 5 mg tablet0.16USD tablet
Methadose 10 mg tablet0.14USD tablet
Dolophine hcl 5 mg tablet0.13USD tablet
Metadol 1 mg/ml Solution0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235.0 °CNot Available
logP3.93HANSCH,C ET AL. (1995)
pKa8.94 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0059 mg/mLALOGPS
logP4.14ALOGPS
logP5.01ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.27 m3·mol-1ChemAxon
Polarizability36.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-00di-9210000000-7542d8c3f742c7713c13View in MoNA
References
Synthesis Reference

Charles J. Barnett, “Modification of methadone synthesis process step.” U.S. Patent US4048211, issued August, 1952.

US4048211
General References
  1. Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis. 1994;13(1):5-26. [PubMed:8018740 ]
  2. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. [PubMed:12405865 ]
  3. Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000 Oct-Nov;67(5-6):347-64. [PubMed:11064485 ]
  4. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. [PubMed:17313907 ]
  5. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL: Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509. [PubMed:16185211 ]
External Links
ATC CodesN02AC52N07BC02
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (327 KB)
MSDSDownload (60 KB)
Interactions
Drug Interactions
Drug
AbacavirThe therapeutic efficacy of Abacavir can be decreased when used in combination with Methadone.
AcepromazineAcepromazine may increase the hypotensive activities of Methadone.
AcetazolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Acetophenazine.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
AlvimopanThe risk or severity of adverse effects can be increased when Methadone is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Methadone is combined with Amiloride.
AminoglutethimideThe serum concentration of Methadone can be increased when it is combined with Aminoglutethimide.
AmisulprideThe risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Methadone which could result in a higher serum level.
AmphetamineAmphetamine may increase the analgesic activities of Methadone.
AnastrozoleThe serum concentration of Methadone can be increased when it is combined with Anastrozole.
AprepitantThe serum concentration of Methadone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Methadone is combined with Aripiprazole.
AzelastineMethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methadone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Bendroflumethiazide.
BenzquinamideThe risk or severity of adverse effects can be increased when Methadone is combined with Benzquinamide.
BexaroteneThe serum concentration of Methadone can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Methadone can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Methadone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Methadone.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
BumetanideThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.
ButorphanolButorphanol may decrease the analgesic activities of Methadone.
CamazepamCamazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
CarbamazepineThe metabolism of Methadone can be increased when combined with Carbamazepine.
CarphenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Carphenazine.
CathinoneCathinone may increase the analgesic activities of Methadone.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlormezanone.
ChlorothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.
ChlorpromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorthalidone.
CinolazepamCinolazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
CitalopramMethadone may increase the QTc-prolonging activities of Citalopram.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ClopidogrelThe metabolism of Methadone can be decreased when combined with Clopidogrel.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ClotiazepamClotiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
CloxazolamCloxazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ClozapineThe risk or severity of adverse effects can be increased when Methadone is combined with Clozapine.
CobicistatThe serum concentration of Methadone can be increased when it is combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Methadone.
ConivaptanThe serum concentration of Methadone can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Methadone can be decreased when combined with Crizotinib.
CyclothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclothiazide.
DabrafenibThe serum concentration of Methadone can be decreased when it is combined with Dabrafenib.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Methadone.
DarunavirThe serum concentration of Methadone can be decreased when it is combined with Darunavir.
DasatinibThe serum concentration of Methadone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Methadone can be decreased when it is combined with Deferasirox.
DesipramineThe metabolism of Methadone can be decreased when combined with Desipramine.
DesmopressinThe risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Methadone.
DofetilideMethadone may increase the QTc-prolonging activities of Dofetilide.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Methadone.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadone.
EfavirenzThe metabolism of Methadone can be increased when combined with Efavirenz.
EluxadolineMethadone may increase the activities of Eluxadoline.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Methadone is combined with Ethacrynic acid.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Methadone.
EthoxzolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Ethoxzolamide.
EtravirineThe serum concentration of Methadone can be decreased when it is combined with Etravirine.
ExemestaneThe serum concentration of Methadone can be increased when it is combined with Exemestane.
FencamfamineThe risk or severity of adverse effects can be increased when Methadone is combined with Fencamfamine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.
FluconazoleThe metabolism of Methadone can be decreased when combined with Fluconazole.
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
FlupentixolThe risk or severity of adverse effects can be increased when Methadone is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Fluphenazine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
FluspirileneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.
FluvoxamineThe metabolism of Methadone can be decreased when combined with Fluvoxamine.
FormestaneThe serum concentration of Methadone can be increased when it is combined with Formestane.
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Methadone resulting in a loss in efficacy.
FosaprepitantThe serum concentration of Methadone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Methadone can be decreased when it is combined with Fosphenytoin.
FurosemideThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.
Fusidic AcidThe serum concentration of Methadone can be increased when it is combined with Fusidic Acid.
GoserelinGoserelin may increase the QTc-prolonging activities of Methadone.
GranisetronGranisetron may increase the serotonergic activities of Methadone.
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
HaloperidolThe risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Hydrochlorothiazide.
HydrocodoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Hydroflumethiazide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
IdelalisibThe serum concentration of Methadone can be increased when it is combined with Idelalisib.
IndapamideThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.
Interferon alfa-n3The serum concentration of Methadone can be increased when it is combined with Interferon alfa-n3.
Interferon alfacon-1The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methadone.
ItraconazoleThe serum concentration of Methadone can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Methadone.
IvacaftorThe serum concentration of Methadone can be increased when it is combined with Ivacaftor.
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
KetoconazoleThe serum concentration of Methadone can be increased when it is combined with Ketoconazole.
LetrozoleThe serum concentration of Methadone can be increased when it is combined with Letrozole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Methadone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Methadone.
LopinavirMethadone may increase the QTc-prolonging activities of Lopinavir.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
LoxapineThe risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methadone.
LuliconazoleThe serum concentration of Methadone can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MequitazineMethadone may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Methadone is combined with Mesoridazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methadone is combined with Methotrimeprazine.
MetoclopramideThe risk or severity of adverse effects can be increased when Methadone is combined with Metoclopramide.
MetolazoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methadone.
MetyrosineMethadone may increase the sedative activities of Metyrosine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Methadone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MitotaneThe serum concentration of Methadone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methadone.
MolindoneThe risk or severity of adverse effects can be increased when Methadone is combined with Molindone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.
NaltrexoneThe therapeutic efficacy of Methadone can be decreased when used in combination with Naltrexone.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Methadone.
NelfinavirThe serum concentration of Methadone can be decreased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Methadone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Methadone can be increased when combined with Nevirapine.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
OctreotideOctreotide may increase the QTc-prolonging activities of Methadone.
OlanzapineThe risk or severity of adverse effects can be increased when Methadone is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Methadone is combined with Ondansetron.
OrphenadrineMethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
PalbociclibThe serum concentration of Methadone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone.
ParaldehydeMethadone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe metabolism of Methadone can be decreased when combined with Paroxetine.
Peginterferon alfa-2aThe serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.
Peginterferon alfa-2bThe serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methadone.
PerphenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methadone.
PhenobarbitalThe serum concentration of Methadone can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Methadone can be decreased when it is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Methadone is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Methadone is combined with Piperacetazine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Methadone.
PramipexoleMethadone may increase the sedative activities of Pramipexole.
PrimidoneThe serum concentration of Methadone can be decreased when it is combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Methadone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methadone.
PromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Promazine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
QuetiapineMethadone may increase the QTc-prolonging activities of Quetiapine.
RamosetronMethadone may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methadone.
RemoxiprideThe risk or severity of adverse effects can be increased when Methadone is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Methadone is combined with Reserpine.
RifampicinThe serum concentration of Methadone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Methadone can be decreased when it is combined with Rifapentine.
RilpivirineThe metabolism of Methadone can be increased when combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Risperidone.
RitonavirThe serum concentration of Methadone can be decreased when it is combined with Ritonavir.
RopiniroleMethadone may increase the sedative activities of Ropinirole.
RotigotineMethadone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methadone.
SaquinavirMethadone may increase the QTc-prolonging activities of Saquinavir.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methadone.
SertindoleThe risk or severity of adverse effects can be increased when Methadone is combined with Sertindole.
SertralineThe metabolism of Methadone can be decreased when combined with Sertraline.
SiltuximabThe serum concentration of Methadone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Methadone can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methadone.
SorafenibThe metabolism of Methadone can be decreased when combined with Sorafenib.
SpironolactoneThe risk or severity of adverse effects can be increased when Methadone is combined with Spironolactone.
St. John's WortThe serum concentration of Methadone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Methadone can be increased when it is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Methadone.
SulpirideThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.
SuvorexantMethadone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Methadone resulting in a loss in efficacy.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Methadone.
TelaprevirThe serum concentration of Methadone can be decreased when it is combined with Telaprevir.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ThalidomideMethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methadone.
ThiotepaThe metabolism of Methadone can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiothixene.
TiclopidineThe metabolism of Methadone can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Methadone is combined with Ticrynafen.
TipranavirThe serum concentration of Methadone can be decreased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.
TofisopamTofisopam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
TorasemideThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methadone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadone.
TriamtereneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.
VilazodoneThe metabolism of Methadone can be decreased when combined with Vilazodone.
VoriconazoleThe serum concentration of Methadone can be increased when it is combined with Voriconazole.
VortioxetineThe metabolism of Methadone can be decreased when combined with Vortioxetine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Methadone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ziprasidone.
ZolpidemMethadone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methadone is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60. [PubMed:11933204 ]
  4. Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008 Jan 15;63(2):172-7. Epub 2007 Sep 11. [PubMed:17850768 ]
  5. Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med (Berl). 2004 Apr;82(4):250-5. Epub 2004 Jan 9. [PubMed:14991152 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009 Oct;60(4):284-90. doi: 10.1016/j.phrs.2009.04.002. Epub 2009 Apr 11. [PubMed:19717013 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402. doi: 10.1213/ANE.0b013e3181b92201. [PubMed:19843777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Deeb TZ, Sharp D, Hales TG: Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol. 2009 Apr;75(4):908-17. doi: 10.1124/mol.108.053322. Epub 2009 Jan 8. [PubMed:19131665 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ: Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6. [PubMed:11408360 ]
  2. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:09